Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution

Area of Science:

• Oncology
• Molecular Biology
• Precision Medicine

Background:

• Rising global cancer incidence and mortality necessitate improved treatment strategies.
• Traditional chemo-immunotherapy faces challenges with toxicity and multidrug resistance.
• Precision medicine and targeted therapies are emerging as promising alternatives.

Purpose of the Study:

• To review clinical trials of kinase inhibitors (KIs) in solid tumor treatment over the past five years.
• To assess the efficacy of KIs as monotherapy or in combination with other agents.

Main Methods:

• Systematic review of clinical trials published within the last five years.
• Focus on studies utilizing kinase inhibitors (KIs) for solid tumor management.
• Analysis of treatment outcomes for KI monotherapy versus combination therapies.

Main Results:

• Kinase inhibitors demonstrate potential in treating solid tumors, offering increased specificity.
• Combination therapies involving KIs, targeted agents, immunotherapy, and chemotherapy show innovation.
• Reported efficacy of KIs varies across different solid tumor types and treatment regimens.

Conclusions:

• Kinase inhibitors represent a significant advancement in targeted cancer therapy.
• Combined therapeutic approaches integrating KIs hold promise for managing recurrent and advanced malignancies.
• Further research is warranted to optimize KI-based treatments and overcome resistance.